BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran as CEO and Idan Elmelech as COO
PUBLIC · BBOTApr 22, 2026
Position
Chief Operating Officer
Company
BridgeBio Oncology Therapeutics
Idan Elmelech
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma
Description
BridgeBio Oncology Therapeutics, Inc. announced the appointment of Pedro J. Beltran, PhD, as Chief Executive Officer and Idan Elmelech as Chief Operating Officer effective April 20th, 2026
Who to call at BridgeBio Oncology Therapeutics, and when
A new leader at BridgeBio Oncology Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day BridgeBio Oncology Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at BridgeBio Oncology Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
BridgeBio Oncology Therapeutics
Location
South San Francisco, California, United States
About
BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company, focuses on RAS-pathway malignancies, specifically developing therapies for patients with KRASG12C mutations. Their lead candidate, BBO-8520, is a first-in-class dual inhibitor targeting both active and inactive forms of KRASG12C, demonstrating significant preclinical efficacy. The company aims to overcome adaptive resistance seen in traditional therapies. Their recent publication highlights the innovative mechanism of action and potential clinical benefits of BBO-8520.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridgeBio Oncology Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma